AXXAM
Bresso, IT · 1 known investors
Axxam develops AXXSense, a cell-based platform for assessing taste and olfactory properties of pharmaceutical compounds during drug development. The platform uses human bitter taste receptors and trigeminal assays to predict bitterness and off-tastes early in the pipeline, helping pharmaceutical companies optimize formulations and reduce late-stage reformulation risks.
Investors · 1
Frequently asked questions
- What does AXXAM do?
- Axxam develops AXXSense, a cell-based platform for assessing taste and olfactory properties of pharmaceutical compounds during drug development. The platform uses human bitter taste receptors and trigeminal assays to predict bitterness and off-tastes early in the pipeline, helping pharmaceutical companies optimize formulations and reduce late-stage reformulation risks.
- Who are AXXAM's investors?
- AXXAM's investors include Keensight Capital.
- Where is AXXAM headquartered?
- AXXAM is headquartered in Bresso, IT.